• Clearmind set plans to expand patent protection in Asia via a Hong Kong filing for novel psychedelic compounds aimed at PTSD.
• Development will advance under its exclusive global license from Yissum, covering development, manufacturing, commercialization, regulatory execution.
• Strategy targets the PTSD therapeutics market, estimated at USD 18.5 billion in 2025, projected at USD 30.2 billion by 2035.
• IP roadmap calls for additional patent filings when warranted, building on 19 patent families with 32 granted patents.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clearmind Medicine Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607200755PRIMZONEFULLFEED9764663) on July 20, 2026, and is solely responsible for the information contained therein.